The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant retatrutide how to reconstitute promise in clinical trials for addressing obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial loss in body weight and